Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024
Notable Labs, Ltd. - Ordinary Shares (NTBL)
Company Research
Source: GlobeNewswire
Poster outlines the parameters for developing a flow-cytometry-based PPMP as a companion diagnostic to predict volasertib responders, based on a proof-of-concept study using 41 primary acute myeloid leukemia (AML) samples Plans to incorporate a dose optimization prelude to enhance patient response and tolerability also outlined in the poster FOSTER CITY, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable” or the “Company”), a clinical-stage precision oncology company developing a new class of cancer therapies identified by its Predictive Precision Medicine Platform (PPMP), today presented the design for the PPMP-enabled Phase 2 trial with volasertib, in combination with decitabine, in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) at the American Association for Cancer Research (AACR 2024) being held in San Diego, CA (Poster abstract 5178). “We are very pleased to share more data regarding our clinical program and proprieta
Show less
Read more
Impact Snapshot
Event Time:
NTBL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NTBL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NTBL alerts
High impacting Notable Labs, Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
NTBL
News
- Notable Labs, Ltd. (NASDAQ: NTBL) had its price target lowered by analysts at Chardan Capital from $7.00 to $5.00. They now have a "buy" rating on the stock.MarketBeat
- Notable Labs to Participate in Fireside Chat at the Citizens JMP Securities Life Sciences Conference 2024GlobeNewswire
- Notable Labs, Ltd. (NASDAQ: NTBL) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $9.00 price target on the stock.MarketBeat
- Notable Labs, Ltd. (NASDAQ: NTBL) had its price target lowered by analysts at Chardan Capital from $9.00 to $7.00. They now have a "buy" rating on the stock.MarketBeat
- Notable Labs Reports 2023 Financial Results and Provides a Business UpdateGlobeNewswire
NTBL
Sec Filings
- 5/15/24 - Form 10-Q
- 5/10/24 - Form 4
- 5/10/24 - Form 4
- NTBL's page on the SEC website